Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
8/2/23	G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
7/31/23	G1 Therapeutics to Participate in Two August Investor Conferences
7/31/23	New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
7/26/23	G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
7/6/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/4/23	Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
6/1/23	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/22/23	G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
5/16/23	New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
5/10/23	New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)